ResearcherUniversity of AntwerpActive in the last 2 years

Maxim Le Compte

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5587-4392; OpenAlex author ID A5007144234. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 8

Papers, trials and grants by year

2023: 1 paper · 2024: 1 paper

Papers 2

Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived organoids, with potentiated efficacy by… Co-author DOI 10.1186/s13046-024-03012-z ↗
Single-organoid analysis reveals clinically relevant treatment-resistant and invasive subclones in pancreatic cancer. Co-author DOI 10.1038/s41698-023-00480-y ↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Christophe Deben · 2 shared papers, 2023–2024 · strength 0.33
- Paper Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived… DOI 10.1186/s13046-024-03012-z ↗
- Paper Single-organoid analysis reveals clinically relevant treatment-resistant and invasive subclones in pancreatic cancer. DOI 10.1038/s41698-023-00480-y ↗
Hans Prenen · 2 shared papers, 2023–2024 · strength 0.33
- Paper Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived… DOI 10.1186/s13046-024-03012-z ↗
- Paper Single-organoid analysis reveals clinically relevant treatment-resistant and invasive subclones in pancreatic cancer. DOI 10.1038/s41698-023-00480-y ↗
Evelien Smits · 2 shared papers, 2023–2024 · strength 0.33
- Paper Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived… DOI 10.1186/s13046-024-03012-z ↗
- Paper Single-organoid analysis reveals clinically relevant treatment-resistant and invasive subclones in pancreatic cancer. DOI 10.1038/s41698-023-00480-y ↗
Geert Roeyen · 2 shared papers, 2023–2024 · strength 0.33
- Paper Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived… DOI 10.1186/s13046-024-03012-z ↗
- Paper Single-organoid analysis reveals clinically relevant treatment-resistant and invasive subclones in pancreatic cancer. DOI 10.1038/s41698-023-00480-y ↗
Marc Peeters · 2 shared papers, 2023–2024 · strength 0.33
- Paper Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived… DOI 10.1186/s13046-024-03012-z ↗
- Paper Single-organoid analysis reveals clinically relevant treatment-resistant and invasive subclones in pancreatic cancer. DOI 10.1038/s41698-023-00480-y ↗
Sofía L. J. Peeters · 1 shared paper, 2023 · strength 0.15
- Paper Single-organoid analysis reveals clinically relevant treatment-resistant and invasive subclones in pancreatic cancer. DOI 10.1038/s41698-023-00480-y ↗
Andreas Domen · 1 shared paper, 2023 · strength 0.15
- Paper Single-organoid analysis reveals clinically relevant treatment-resistant and invasive subclones in pancreatic cancer. DOI 10.1038/s41698-023-00480-y ↗
Timon Vandamme · 1 shared paper, 2023 · strength 0.15
- Paper Single-organoid analysis reveals clinically relevant treatment-resistant and invasive subclones in pancreatic cancer. DOI 10.1038/s41698-023-00480-y ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.